An extraordinary meeting will take place next month to vote on new members after the company and its controlling shareholder failed to agree on the board's composition. ...

Group 1 - The chair of Novo Nordisk and six independent board members will resign due to a strategic dispute with the controlling shareholder, the Novo Nordisk Foundation [1][3] - The Foundation plans to propose Lars Rebien Sorensen as the temporary chairman for a period of two to three years [2] - The company has undergone significant leadership changes, including the ousting of CEO Lars Fruergaard Jorgensen and the initiation of a restructuring plan involving 9,000 job cuts [2] Group 2 - The board renewal is deemed necessary by the Foundation to adapt to the rapidly changing environment in the obesity drug market [3] - There was a lack of consensus between the board and the Foundation regarding the extent of the board renewal, with the board favoring selective additions and the Foundation advocating for a more comprehensive reconfiguration [4] - Helge Lund has served as chair of Novo's board since 2018 [4]

Core Insights - Novo Nordisk, the maker of Ozempic, is undergoing significant changes in its board structure to enhance governance and strategic direction [1] Group 1: Company Changes - The company is appointing new board members to bring diverse expertise and perspectives [1] - These changes are part of a broader strategy to adapt to the evolving healthcare landscape and address shareholder concerns [1] Group 2: Market Impact - The restructuring is expected to strengthen Novo Nordisk's position in the competitive pharmaceutical market, particularly in diabetes and obesity treatments [1] - Investors are closely monitoring these developments as they may influence the company's future performance and stock valuation [1]

Novo Nordisk U.S. President Dave Moore confirms the company is in active discussions with the Trump administration over most favored nation pricing for its popular GLP-1 drugs Ozempic and Wegovy, as it wraps up talks for the IRA Medicare drug price negotiations. It comes as the company is ramping up its U.S. manufacturing capabilities ahead of the anticipated approval of Wegovy in pill form. Moore spoke exclusively with CNBC’s Bertha Coombs at the HLTH conference in Las Vegas ...

Dave Moore, thanks so much for sitting down and chatting with us. On Friday, the FDA approved rebels for yet another indication. Rebelsis is a pill form of simaglletide.This is one of the things that everyone is watching. What does that mean for you as you get another indication for rebelsis and what does that mean for the manufacturing of those pills. >> Yeah, thanks Bertha.It's great to be with you here at health. It's a really exciting conference. Uh we were very pleased to receive the approval on Friday ...

Core Viewpoint - Novo Nordisk is experiencing a leadership shake-up as several board members will resign following disagreements with the controlling shareholder regarding the board's future composition [2][3]. Group 1: Board Composition and Changes - The board proposed a renewal that focuses on adding new competencies while maintaining continuity, but the Novo Nordisk Foundation sought a more extensive reconfiguration [2]. - Key board members, including Chair Helge Lund and Vice Chair Henrik Poulsen, will not stand for election at the upcoming Extraordinary General Meeting scheduled for November 14 [3]. Group 2: Market Reaction - Following the announcement, shares of Novo Nordisk traded 1.2% lower as of 1:41 p.m. London time [3].

格隆汇10月21日｜诺和诺德股价在提议选举新一届董事会成员后下跌1%。 ...

Novo Nordisk Chairman Helge Lund is stepping down and and will be replaced by Lars Rebien Sorensen https://t.co/i3akX3Wlcy ...

格隆汇10月21日｜诺和诺德宣布将召开临时股东大会，以选举董事会新成员。 ...

Core Viewpoint - Novo Nordisk announced that its Chair Helge Lund and six other board members will resign at an extraordinary general meeting scheduled for November 14 [1] Group 1 - The resignation of the Chair and board members indicates potential changes in corporate governance [1] - The timing of the extraordinary general meeting suggests a significant shift in the company's leadership structure [1]